Abstract: Objective To explore the effect of diterpene ginkgolides meglumine injection(DGMI)on the level of plasma type Ⅰ plasminogen activator inhibitor(PAI-1)and neurological function in patients with acute cerebral infarction. Methods Eighty patients with acute cerebral infarction were selected and randomly divided into DGMI group and control group, with 40 cases in each group. The DGMI group was treated with intravenous infusion of DGMI for 25 mg per day for 14 days, while the control group was given basic treatment without DGMI. The degree of neurological deficit, parameters of thromboelastography(TEG)and plasma PAI-1 level were compared between the two groups before and after 14 days of treatment. Results After 14 days of treatment, the National Institutes of Health Stroke Scale(NIHSS)score and Barthel index in both groups were significantly better than those before treatment, and the NIHSS score and Barthel index of the DGMI group were significantly better than those of the control group(P<0.05). After 14 days of treatment, the R value and K value of TEG in the DGMI group were significantly higher than those before treatment, while degree of Angel and MA value were significantly lower than those before treatment(P<0.05). After treatment, the MA value in the control group showed significant difference when compared to treatment before(P<0.05). The R value and K value of the DGMI group were significantly higher than those of the control - group, while the degree of Angel and MA value were significantly lower than those of the control group (P<0.05). After treatment, the plasma PAI-1 level in the DGMI group was significantly lower than that treatment before and the control group(P<0.05). Conclusion DGMI may affect the activity of coagulation and fibrinolysis system by regulating the plasma level of PAI-1, thereby improving the symptoms of neurological deficit in patients.